Parkinson's disease: Still waiting for a cure.
作者信息
Kwok D Kevin
机构信息
Parkinson's Patient Advocate, Boulder, Colorado, USA.
出版信息
Clin Transl Sci. 2024 Jul;17(7):e13898. doi: 10.1111/cts.13898.
Abstract
摘要
相似文献
1
Parkinson's disease: Still waiting for a cure.帕金森病：仍在等待治愈方法。
Clin Transl Sci. 2024 Jul;17(7):e13898. doi: 10.1111/cts.13898.
2
Treatment of Parkinson's disease.帕金森病的治疗。
N Engl J Med. 1993 Sep 30;329(14):1021-7. doi: 10.1056/NEJM199309303291408.
3
Parkinson's disease.帕金森病
Nature. 2010 Aug 26;466(7310):S1. doi: 10.1038/466S2a.
4
Parkinson's disease: summary of updated NICE guidance.帕金森病：英国国家卫生与临床优化研究所（NICE）最新指南摘要
BMJ. 2017 Jul 27;358:j1951. doi: 10.1136/bmj.j1951.
5
[New prospects for therapy in Parkinson's disease].[帕金森病治疗的新前景]
Drug Res (Stuttg). 2013 Nov;63 Suppl 1:S23. doi: 10.1055/s-0033-1346718. Epub 2013 Nov 15.
6
[Pharmacotherapy of Parkinson's disease].[帕金森病的药物治疗]
MMW Fortschr Med. 2013 May 2;155(8):49-51. doi: 10.1007/s15006-013-0640-7.
7
Current issues in the diagnosis and treatment of Parkinson's disease. Introduction.帕金森病诊断与治疗的当前问题。引言。
Int J Neurosci. 2011;121 Suppl 2:1-2. doi: 10.3109/00207454.2011.622454.
8
[Tolcapone treatment of late stages of Parkinson's disease].[托卡朋治疗帕金森病晚期]
Zh Nevrol Psikhiatr Im S S Korsakova. 2005;105(6):31-4.
9
The effects of deep brain stimulation and levodopa on postural sway in subjects with Parkinson's disease.深部脑刺激和左旋多巴对帕金森病患者姿势摇摆的影响。
J Neurol Neurosurg Psychiatry. 2002 Sep;73(3):240. doi: 10.1136/jnnp.73.3.240.
10
Deep brain stimulation for Parkinson's disease.用于帕金森病的深部脑刺激
Med Lett Drugs Ther. 2009 Apr 6;51(1309):26-7.
本文引用的文献
1
A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research.神经元α-突触核蛋白病的生物学定义：建立研究用综合分期系统。
Lancet Neurol. 2024 Feb;23(2):178-190. doi: 10.1016/S1474-4422(23)00405-2.
2
Medical, surgical, and physical treatments for Parkinson's disease.帕金森病的医学、手术和物理治疗。
Lancet. 2024 Jan 20;403(10423):305-324. doi: 10.1016/S0140-6736(23)01429-0.
3
The pathogenesis of Parkinson's disease.帕金森病的发病机制。
Lancet. 2024 Jan 20;403(10423):293-304. doi: 10.1016/S0140-6736(23)01478-2.
4
The epidemiology of Parkinson's disease.帕金森病的流行病学。
Lancet. 2024 Jan 20;403(10423):283-292. doi: 10.1016/S0140-6736(23)01419-8.
5
The elephant in the room: critical reflections on mortality rates among individuals with Parkinson's disease.房间里的大象：对帕金森病患者死亡率的批判性思考
NPJ Parkinsons Dis. 2023 Oct 19;9(1):145. doi: 10.1038/s41531-023-00588-9.
6
Transforming Drug Development for Neurological Disorders: Proceedings from a Multidisease Area Workshop.转化神经疾病药物研发：多疾病领域研讨会论文集
Neurotherapeutics. 2023 Oct;20(6):1682-1691. doi: 10.1007/s13311-023-01440-x. Epub 2023 Oct 12.
7
An Interview With the Food and Drug Administration About Draft Patient-Focused Drug Development Guidance 3: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments.对美国食品药品监督管理局就《以患者为中心的药物研发指南3：选择、开发或修改适用的临床结局评估》草案的访谈
Value Health. 2023 Jun;26(6):791-795. doi: 10.1016/j.jval.2023.04.006. Epub 2023 Apr 26.
8
Central and peripheral α-synuclein in Parkinson disease detected by seed amplification assay.帕金森病中通过种子扩增检测到的中枢和外周 α-突触核蛋白。
Ann Clin Transl Neurol. 2023 May;10(5):696-705. doi: 10.1002/acn3.51753. Epub 2023 Mar 27.
9
Measuring What Matters to Patients in Dermatology Drug Development: A Regulatory Perspective.衡量皮肤科药物研发中对患者重要的指标：监管视角。
Dermatol Clin. 2022 Jul;40(3):333-337. doi: 10.1016/j.det.2022.03.002. Epub 2022 Jun 1.
10
Longitudinal Change of Clinical and Biological Measures in Early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort.早期帕金森病临床和生物学指标的纵向变化：帕金森进展标志物倡议队列。
Mov Disord. 2018 May;33(5):771-782. doi: 10.1002/mds.27361. Epub 2018 Mar 23.
Zotero 插件